Management of Penile Fibrosis from Intracavernosal Alprostadil

Initial Management and Monitoring

The American Urological Association recommends continuing regular follow-up with careful penile examination at 3-month intervals to monitor for progression or improvement, examining for penile nodules, plaques, curvature, and areas of induration at each follow-up visit 1
Monitoring erectile function and treatment efficacy is crucial, as fibrosis may impact response to therapy, and ensure proper injection technique through retraining to avoid treatment failure and complications 1

The European Association of Urology suggests transitioning to PDE5 inhibitors (sildenafil, tadalafil, vardenafil) as first-line therapy if the patient has not already failed these agents, and consider intraurethral alprostadil as an alternative to avoid direct corporal trauma 2, 3, 4
Vacuum erection devices (VED) with vacuum limiters are an option that avoids further penile trauma, though patients should be counseled about minor adverse effects like petechiae and discomfort 2, 3, 5

The American Urological Association recommends considering penile prosthesis implantation if erectile dysfunction becomes refractory to medical management and fibrosis significantly impairs quality of life, with patients being counseled regarding post-operative expectations and potential complications 2, 3, 5

Patients should be educated on priapism warning signs and have a clear action plan for erections lasting ≥4 hours, and for prolonged erections <4 hours, intracavernosal phenylephrine is the initial treatment to prevent progression to ischemic priapism 1, 6, 7
Monitoring blood pressure and heart rate during phenylephrine administration is essential, especially in patients with cardiovascular disease 7